Acute Lung Injury Market 2025 Research Report By End-user (Hospitals, Specialty Centers, and Others), By Therapy (Mechanical Ventilation, Pharmacotherapy, Fluid Management, and Others), and by Region- Global Forecast to 2034
May-2025 Formats | PDF | Category: Healthcare | Delivery: 24 to 72 Hours
Keep in mind that the market’s outlook is being impacted by the swift changes in global trade ties and tariffs. Prior to delivery, the report will be updated with the most recent information, including updated forecasts and a quantified impact analysis. The sections on recommendations and conclusions in the report will be revised to provide methods for organisations coping with the rapidly changing global environment.
“The Acute Lung Injury Market is expected to expand from 3.5 Billion in 2025 to $4.7 Billion in 2034, with a compound annual growth rate of 3.86% “
One thriving and rapidly evolving segment of the healthcare industry is the market for acute lung injuries. This article will analyse the current status of the acute lung injury market and highlight significant developments and trends to watch in the upcoming year.
Acute lung injury, also known as acute respiratory distress syndrome (ARDS), is a potentially lethal condition that affects the lungs’ ability to oxygenate blood. Inflammation and fluid buildup in the lungs cause severe respiratory failure.
The market for acute lung injuries is being driven by a number of factors, including advancements in medical technology, an increase in the prevalence of respiratory illnesses, and an increase in public awareness of the problem. According to research, the industry is expected to grow significantly over the coming years, with a focus on developing innovative therapies and treatments for ARDS.
Major players in the acute lung injury market include pharmaceutical companies, medical device manufacturers, research institutes, and healthcare providers. These stakeholders actively participate in research and development initiatives to bring new and improved therapies to the market.
One of the key developments in the market for acute lung injury is the focus on personalised medicine and precision therapies. Companies are investing more in research to develop specialised treatments that can be tailored to the individual needs of each patient.
Some of the possible opportunities in the acute lung injury market include the creation of novel treatments, expanding the market to developing nations, and forming alliances with academic institutions and healthcare providers. These factors are expected to drive the market in the years to come.
Although the acute lung injury market has encouraging growth potential, it faces several challenges, including regulatory barriers, high research costs, and the need for solid clinical data to support innovative treatments. These obstacles need to be removed if the market is to reach its maximum potential.
For Insights Consultancy’s latest market intelligence study, “Global Acute Lung Injury Market 2025, Growth Opportunities, and Forecast,” provides a comprehensive analysis of the Food industry. The report includes demand analysis, industry insights, competition intelligence, and a customer database. It also offers strategic insights into future trends, growth determinants, supplier landscape, demand landscape, CAGR, and pricing analysis. The study also includes Porter’s Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps’ Analysis, Market Attractiveness Analysis, BPS Analysis, and Ecosystem Analysis.
*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 110+ is available for purchase to all the interested stakeholders.
Top Companies Covered In This Report:
- Mayo Clinic
- Johns Hopkins Hospital
- Altor BioScience
- FirstString Research
- GlaxoSmithKline
- Forschung und Entwicklung
- Commence Bio
- CompleGen
- Histocell S.L.
- Stemedica Cell Technologies
- Windtree Therapeutics
- S-Evans Biosciences
- KYORIN Pharmaceutical Co
- Implicit Bioscience Ltd
- Faron Pharmaceuticals Ltd.
- Carolus Therapeutics Aster Hospitals
Industry News
May 23, 2025 GSK’s asthma drug wins FDA approval to treat ‘smoker’s lung’
The U.S. Food and Drug Administration has approved British drugmaker GSK’s (GSK.L), opens new tab asthma drug to treat some patients with a chronic lung disease commonly known as “smoker’s lung”, the company said. The approval expands the use of the drug, Nucala, as an add-on treatment for patients with a type of chronic obstructive pulmonary disease.
02 May 2025 GSK continues to advance the future of respiratory medicine and patient care with new data at ATS
GSK plc announced data from across its respiratory portfolio will be presented in 43 abstracts, including four late-breaking submissions, at the 2025 American Thoracic Society (ATS) International Congress in San Francisco (16 – 21 May). Key presentations aim to strengthen our understanding of optimal patient care to advance the prevention and treatment of diseases like asthma and chronic obstructive pulmonary disease (COPD).
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2034, Y-o-Y growth rate, and CAGR):
Segment By End-user
- Hospitals
- Specialty Centers
- Others
Segment By Therapy
- Mechanical Ventilation
- Pharmacotherapy
- Fluid Management
- Others
Regional Deep-dive Analysis:
The report provides in-depth qualitative and quantitative data on the Acute Lung Injury Market for all of the regions and countries listed below:
North America includes the United States, Canada, and Mexico.
Europe includes Germany, France, Italy, the United Kingdom, Scandinavia, Benelux, Russia, and the rest of Europe.
Asia-Pacific includes Japan, South Korea, India, China, Southeast Asia, and Australia.
South America (including Brazil, Argentina, and the rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa)
Each country is studied in detail, and the study includes qualitative and quantitative analysis of the Acute Lung Injury Market in that country.
North America
North America is a significant player in the acute lung injury market, with the US leading the way in research and development. Some of the factors driving the US market include the increased prevalence of respiratory diseases, technological advancements in treatment options, and growing awareness among healthcare professionals.
Canada
Canada is also turning into a very lucrative market for acute lung injury treatments. The robust healthcare system in the country and the high demand for innovative treatments are driving the market’s expansion.
Mexico
In Mexico, the use of treatments for acute lung damage is growing. Numerous factors, such as a large patient base, rising healthcare spending, and rising disposable income, are contributing to the country’s market expansion.
Europe:A Hub of Innovation in ALI Treatment
United Kingdom
In the UK, pharmaceutical companies and research facilities are setting the standard for developing novel ALI treatments. With a strong focus on patient outcomes and clinical trials, the UK is a fierce rival in the European market.
Germany
Germany invests heavily in medical research and has a robust healthcare system. As a result, German companies are leading the way in ALI treatment developments, emphasising targeted medications and customised therapy.
France
France is home to some of the world’s leading respiratory medicine specialists, making it a hub for cutting-edge research in the management of acute lung injury (ALI). In the fiercely competitive and ever-changing French market for ALI treatments, quality of care is crucial.
Italy
Italy has a long history of excellence in medical research, particularly in the field of critical care. Italian doctors and researchers are actively developing novel ALI treatment approaches with a focus on patient-centered care.
Spain
Spain’s expanding biotech sector is driving innovation in the treatment of ALI. Spanish companies are using the country’s strong academic and research infrastructure to develop possible new treatments for this challenging illness.
Asia-Pacific
China
China is a significant player in the acute lung injury market, driving demand for innovative treatments due to its expanding population and growing healthcare costs. Research and development is highly valued in the country, and several well-known pharmaceutical companies have made large investments in the area. Government efforts to improve healthcare infrastructure and access to high-quality services are driving the industry’s growth.
Japan
Japan’s advanced healthcare system and cutting-edge medical technologies make it a significant market for acute lung injury treatments. Because of the country’s high incidence of respiratory diseases and ageing population, there is an urgent need for effective treatments. Initiatives to support innovation and regulatory reforms are helping Japan’s market grow.
India
India’s large and diverse patient base makes it a rapidly growing market for acute lung injury treatments. As a result of increased R&D spending, the country’s healthcare sector is growing dramatically. The market in India is growing as a result of rising awareness of respiratory conditions and the availability of affordable treatment options.
South Korea
South Korea is a sizable market for medications for acute lung injury, with a strong focus on precision medicine and individualised healthcare. The country’s robust infrastructure and state-of-the-art medical facilities make it an attractive destination for market players. The South Korean market is expanding as a result of government funding for research and development as well as an increasing focus on digital health technology.
Australia
Australia is a developed market for acute lung injury treatments, with a robust healthcare system and high standards of care. The country’s emphasis on innovation and high-quality research has led to the development of new medications and treatment modalities. Strong collaborations between academic institutions and industry stakeholders are driving market developments.
Middle East and Africa
The Middle East has seen a steady rise in the number of cases of acute lung damage in recent years. The increased prevalence of risk factors like smoking, respiratory infections, and air pollution has contributed to this trend. Middle Eastern countries like Saudi Arabia, the United Arab Emirates, and Qatar have been investing heavily in healthcare research and infrastructure in an effort to address the issue.
Saudi Arabia
To raise public awareness of the importance of respiratory health and early intervention, for example, the Saudi Arabian government has started a number of programmes and campaigns. In order to facilitate prompt diagnosis and treatment of acute lung injury cases, advanced technologies have also been installed in the country’s healthcare facilities.
In the United Arab Emirates, similar steps have been taken to improve air quality and reduce pollution to reduce the risk of respiratory illnesses. The government has also enforced stringent regulations on smoking and tobacco use to prevent lung-related illnesses.
Africa:
In Africa, acute lung injury remains a serious health concern, particularly in countries with limited access to healthcare. Due to inadequate infrastructure and medical facilities, it has proven challenging to diagnose and treat respiratory disorders in many African nations.
However, countries like South Africa have made great progress in addressing the issue of acute lung injury. The South African government has invested in research and development to enhance treatment results and raise awareness of respiratory disorders. Partnerships with international organisations and medical facilities have also made it easier for people to access state-of-the-art treatments for acute lung injury.
The research provides answers to the following key questions:
- What is the expected growth rate of the Acute Lung Injury Market from 2025-2034?
- What are the key driving forces shaping the market during the forecast period?
- Who are the major market vendors and what winning strategies have helped them occupy a strong foothold in the Acute Lung Injury Market?
- What are the prominent market trends influencing the market’s development?
Key insights provided by the report that could help you take critical strategic decisions?
- Regional reports analyse product/service consumption and market factors in each region.
- Reports highlight possibilities and dangers for suppliers in the Acute Lung Injury Market business globally.
- The report identifies regions and sectors with the highest growth potential.
- It provides a competitive market ranking of major companies, as well as information on new product launches, partnerships, business expansions, and acquisitions.
- The report includes a comprehensive corporate profile with company overviews, insights, product benchmarks, and SWOT analysis for key market participants.
Customization: We can provide following things
1) On request more company profiles (competitors)
2) Data about particular country or region
3) We will incorporate the same with no additional cost (Post conducting feasibility).
Any Requirement Contact us: https://forinsightsconsultancy.com/contact-us/
Table of Contents
For TOC Contact us: https://forinsightsconsultancy.com/contact-us/
